Pearl Steinzor

The first study of its kind links nighttime light exposure to structural heart changes among over 11,000 adults followed for 3 years.

GLP-1 prescribing among children aged 8 to 11 years with obesity rose 310-fold from 2019 to 2026, but use remains rare and unevenly distributed by income.

Trejeeve Martyn, MD, shares why finerenone belongs on formulary, and how pharmacist-led access models can work in smaller health systems.

The combination therapy met the primary OS end point vs durvalumab alone as first-line ES-SCLC maintenance therapy in the phase 3 DeLLphi-305 trial.

Optum Health's Ken Cohen, MD, FACP, discusses findings from a recent study linking elective PVI to higher limb loss and costs.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

A random survival forest model trained on 850 patients outperformed the Mayo Clinic and National Amyloidosis Centre staging systems for ATTR-CM.

PVI for intermittent claudication was associated with more than double the rate of major adverse limb events and higher costs of care.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

A cohort study found lower breast cancer screening odds in the most redlined census tracts, independent of present-day social vulnerability.

A randomized crossover trial found dose-dependent driving impairment from THC edibles at blood concentrations below common per se limits.

Five-year EXPLORER-LTE data show sustained LVOT gradient reductions and NYHA class improvements in patients with obstructive HCM.

A VESALIUS-CV analysis found a 20% reduction in all-cause death with evolocumab in patients without prior MI or stroke, emerging after 1.5 years.

Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists anticipate decline.

Part D plans are navigating intensifying pressure from GLP-1 therapies, which combine relatively high per-patient costs with a massive eligible population.

FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations.

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy People 2030 target in 2019.

AHIP's Jeanette Thornton details health care's prior authorization commitments as a 2027 real-time approval target approaches.

The phase 4 study will track serum transthyretin and other biomarkers in 50 adults with ATTR-CM switching from tafamidis to acoramidis over 6 months.

Medicare Part D changes, premium stabilization expiration, and a Bridge demonstration converge with rising GLP-1 demand and costs.

John Anderson, MD, explains why stronger primary care and specialist collaboration are needed in diabetes care.

The approval is based on the Phase 2/3 ENERGY trial, which demonstrated durable hemoglobin response.

A study shows mobile integrated health was well received by patients and clinicians despite barriers to broader implementation.

More prediabetes screening, earlier GLP-1/SGLT2 inhibitor use, and broader CGM access in type 2 diabetes are needed, says John Anderson, MD.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in resected stage IIB-IV melanoma.

A secondary analysis of the HELIOS-B trial found that worse left atrial strain was associated with higher risks of mortality and cardiovascular events.

Heidi Overton, MD, PhD, a physician and White House health policy aide, would replace acting commissioner Kyle Diamantas, JD.

Frequent adolescent sexual assault and discrimination in employment, housing, and police interactions was associated with higher heart failure risk.

Experts discuss why patients with HFmrEF/HFpEF still receive less urgent, less standardized care than those with reduced ejection fraction.